Monday, January 4, 1999
The ability of cancer cells to pump out chemotherapeutics has made that
capability an increasingly popular target for cancer drugs. However, in any given cancer
cell, it is unknown which or how many human proteins might contribute to multidrug
Thus companies hoping to increase the efficacy of chemotherapeutics by
inhibiting the MDR transporters have two strategic choices: to develop broad-spectrum
agents capable of inhibiting the entire family or focus their efforts on cancers where the
specific transporters being targeted are known to be responsible for resistance.